Articles Tagged With:
-
CDC: Give Immediate Antivirals to High Risk Patients with Flu Symptoms
Emergency physicians might opt to prescribe antivirals to any patient with the flu, but high-risk patients definitely should receive them, according to public health officials.
-
OHRP’s standard of care draft guidance elicits praise, criticism
Critics and supporters both have weighed in on recent standard of care guidance published by the Office for Human Research Protections (OHRP). -
TV Medical Advice and Your Patients
The next time a patient responds to your diagnosis or suggestion with, “But Dr. Oz says...,” caution them about their sources.
-
Ebola Assessment Centers Will Make Speedy Diagnoses, Transfers
Here are details on the role those facilities and their EDs will play in the CDC’s effort to prepare for more Ebola cases in the US.
-
Example author description article
-
[SAMPLE] Table 1: Summary of Painless Vision Loss
-
[SAMPLE] Evaluation and Management of Sudden Vision Loss: Part II
This issue is the second part of our discussion of sudden vision loss, stressing conditions that present to the emergency department. You will note the utility of ocular ultrasound in diagnosing many of these conditions. This review was helpful to me as a practicing emergency physician. -- J. Stephan Stapczynski, MD, FACEP, Editor -
[SAMPLE] Test Article with Image Gallery
-
DAPT Trial Adds Both Clarity and Confusion to the Debate Over Optimal Duration of Dual Antiplatelet Therapy
Dual antiplatelet therapy (DAPT) following coronary stenting is essential for the prevention of stent thrombosis, which can occur due to a response to the vascular scaffold, as well as to the local inflammation that occurs after angioplasty. DAPT after drug-eluting stent (DES) implantation is currently recommended for at least 12 months in the United States and for 6 months in Europe. Concern over very late stent thrombosis (occurring later than 1 year) with DES prompted a collaborative effort between the FDA and device and pharmaceutical manufacturers to study the efficacy of DAPT beyond 1 year in these patients. -
[No headline]